Castalagin exerts inhibitory effects on osteoclastogenesis through blocking a broad range of signaling pathways with low cytotoxicity

Phytotherapy Research

Volumn 29, Issue 6, 2015, Pages 917-924

  Iwatake, Mayumi ^a   Okamoto, Kuniaki ^a   Tanaka, Takashi ^a   Tsukuba, Takayuki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

castalagin; NFATc1; osteoclasts; RANKL

Indexed keywords

CASTALAGIN; CATHEPSIN K; CYTOPLASM PROTEIN; CYTOPLASMIC 1; HEME OXYGENASE 1; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; POLYPHENOL; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; TANNIN; TRANSCRIPTION FACTOR NFAT; VESCALAGIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE; MALE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; DRUG EFFECTS; METABOLISM; OSTEOCLAST; PHOSPHORYLATION;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; HEME OXYGENASE-1; HYDROLYZABLE TANNINS; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHORYLATION; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84930659336     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5333     Document Type: Article

References (20)

1. Boyle WJ, Simonet WS, Lacey DL,. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
2. Darnay BG, Ni J, Moore PA, Aggarwal BB,. 1999. Activation of NF-kappa B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappa B-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274: 7724-7731.
3. Fridrich D, Glabasnia A, Fritz J, et al,. 2008. Oak ellagitannins suppress the phosphorylation of the epidermal growth factor receptor in human colon carcinoma cells. J Agric Food Chem 56: 3010-3015.
4. Fumimoto R, Sakai E, Yamaguchi Y, et al,. 2012. The coffee diterpene kahweol prevents osteoclastogenesis via impairment of NFATc1 expression and blocking of Erk phosphorylation. J Pharmacol Sci 118: 479-486.
5. Ha H, Kwak HB, Lee SW, et al,. 2004. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301: 119-127.
6. Hager TJ, Howard LR, Liyanage R, Lay JO, Prior RL,. 2008. Ellagitannin composition of blackberry as determined by HPLC-ESI-MS and MALDI-TOF-MS. J Agric Food Chem 56: 661-669.
7. He B, Hu M, Li SD, et al,. 2013. Effects of geraniin on osteoclastic bone resorption and matrix metalloproteinase-9 expression. Bioorg Med Chem Lett 23: 630-634.
8. Hotokezaka H, Sakai E, Kanaoka K, et al,. 2002. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277: 47366-47372.
9. Hu JP, Nishishita K, Sakai E, et al,. 2008. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappa B and Akt pathways. Eur J Pharmacol 580: 70-79.
10. Kamiya T, Kobayashi Y, Kanaoka K, et al,. 1998. Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts. J Biochem 123: 752-759.
11. Lee NK, Choi YG, Baik JY, et al,. 2005. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106: 852-859.
12. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M,. 2000. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275: 31155-31161.
13. Narahara S, Matsushima H, Sakai E, et al,. 2012. Genetic backgrounds and redox conditions influence morphological characteristics and cell differentiation of osteoclasts in mice. Cell Tissue Res 348: 81-94.
14. Park EK, Kim MS, Lee SH, et al,. 2004. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation. Biochem Biophys Res Commun 325: 1472-1480.
15. Sakai E, Shimada-Sugawara M, Nishishita K, et al,. 2012. Suppression of RANKL-dependent heme oxygenase-1 is required for high mobility group box 1 release and osteoclastogenesis. J Cell Biochem 113: 486-498.
16. Sakai E, Shimada-Sugawara M, Yamaguchi Y, et al,. 2013. Fisetin inhibits osteoclastogenesis through prevention of RANKL-induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes. J Pharmacol Sci 121: 288-298.
17. Shuaibu MN, Pandey K, Wuyep PA, et al,. 2008. Castalagin from Anogeissus leiocarpus mediates the killing of Leishmania in vitro. Parasitol Res 103: 1333-1338.
18. Teitelbaum SL,. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
19. Vivas N, Laguerre M, Pianet de Boissel I, Vivas de Gaulejac N, Nonier MF,. 2004. Conformational interpretation of vescalagin and castalagin physicochemical properties. J Agric Food Chem 52: 2073-2078.
20. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y,. 2001. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276: 563-568.